Skip to main content
Fig. 1 | Cancer Nanotechnology

Fig. 1

From: Enhanced cancer immunotherapy through synergistic ferroptosis and immune checkpoint blockade using cell membrane-coated nanoparticles

Fig. 1

Characterization of the PD-1 membrane-coated ferroptosis nanoinducer. a CLSM imaging analysis of PD-1-GFP expression in the HEK-293 T-PD-1 stable cell line. Scale bar: 20 μm. b Size distribution and morphology analysis of PD-1@RSL3 NPs. Scale bar: 50 nm. c Surface charge of RSL3 NPs, PD-1 NVs, Blank@RSL3 NPs, and PD-1@RSL3 NPs. d Western blot analysis confirmed the PD-1 expression in PD-1@RSL3 NPs. e In vitro stability analysis of PD-1@RSL3 NPs by measuring the size changes at 4 ℃. f. Drug release profile of PD-1@RSL3 NPs in vitro

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us